Claims
- 1. A method for modulating human N-type calcium channel α1B+SFVG subunit activity, comprising administering to a subject in need thereof an effective amount of a compound of formula (I), (II), or (III):
- 2. A method for modulating human N-type calcium channel α1B+SFVG subunit activity, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (IV) or (V) or a pharmaceutically acceptable salt thereof:
- 3. The method of claim 2, wherein Ar represents one or two unsubstituted phenyl moieties.
- 4. The method of claim 2 wherein n2 is 1 and X2 represents a linker which spaces Ar from Z at a distance of about 3-20 Å.
- 5. The method of claim 2 wherein Cy represents one or two unsubstituted cyclohexyl moieties or an unsubstituted cyclohexyl moiety and an unsubstituted phenyl moiety.
- 6. The method of claim 2 wherein X1 represents a linker which spaces the Ya and Yb from N at a distance of about 3-20 Å.
- 7. A method for modulating human N-type calcium channel α1B+SFVG subunit activity, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (VI) or a pharmaceutically acceptable salt thereof:
- 8. The method of claim 7 wherein the compound has formula (VII):
- 9. The method of claim 8 wherein Y is CH═CHΦ.
- 10. The method of claim 8 wherein Y is Cy.
- 11. The method of claim 8 wherein Y is Φ2CH.
- 12. The method of claim 8 wherein n is 0 or 1 and Y is Φ.
- 13. The method of claim 7, wherein the compound is:
- 14. The method of claim 7, wherein the compound is:
- 15. A method for modulating human N-type calcium channel α1B+SFVG subunit activity, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (VIII) or a pharmaceutically acceptable salt thereof:
- 16. The method of claim 15 wherein at least one of R1, R2 and R3 is a halo substituent.
- 17. The method of claim 15, wherein the compound has formula (IX):
- 18. The method of claim 15 wherein the compound has formula (X):
- 19. A method for modulating human N-type calcium channel α1B+SFVG subunit activity, the method comprising administering to a subject in need thereof an effective amount of a compound comprising:
a straight backbone carbon chain of C8-16C, optionally substituted with 1-15 alkyl groups (C1-C6); said chain optionally functionalized at one terminus with halo, —OR, SR, NR2, —OOCR, —NROCR wherein R is alkyl (C1-C6), or phosphate or pyrophosphate, or functionalized wherein a terminal carbon is optionally in the form or —COOR, —CONR2 or —COR wherein R is alkyl (C1-C16); and wherein said chain may optionally contain 1-4 π-bonds or the epoxides thereof.
- 20. A method of making a human N-type calcium channel α1B+SFVG modulating compound, the method comprising synthesizing a compound of formula (I), (II), or (III) in claim 1 and contacting the compound with a human N-type calcium channel α1B+SFVG subtype.
- 21. The method of claim 20, further comprising measuring the modulation of calcium channel activity.
- 22. The method of claim 21, wherein the contacting is conducted in vitro.
- 23. A storage medium comprising chemical structure information of a compound of formula (I), (II), or (III) in claim 1 and calcium channel actvity of a human N-type calcium channel α1B+SFVG when in contact with the compound.
- 24. A method of evaluating information comprising integrating the storage medium the storage medium of claim 23 with a computer system for evaluation or drug discovery or design.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 60/414,738, filed on Sep. 30, 2002. The contents of this application is incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60414738 |
Sep 2002 |
US |